<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29431731</article-id>
<article-id pub-id-type="pmc">5824853</article-id>
<article-id pub-id-type="publisher-id">94996</article-id>
<article-id pub-id-type="doi">10.1172/JCI94996</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Physiological genomics identifies genetic modifiers of long QT syndrome type 2 severity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chai</surname>
<given-names>Sam</given-names>
</name>
<email>sam.sl.chai@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Xiaoping</given-names>
</name>
<email>xwan@metrohealth.org</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramirez-Navarro</surname>
<given-names>Angelina</given-names>
</name>
<email>arnavarro@metrohealth.org</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tesar</surname>
<given-names>Paul J.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaufman</surname>
<given-names>Elizabeth S.</given-names>
</name>
<email>ekaufman@metrohealth.org</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ficker</surname>
<given-names>Eckhard</given-names>
</name>
<email>eficker@metrohealth.org</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>George</surname>
<given-names>Alfred L.</given-names>
<suffix>Jr.</suffix>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deschênes</surname>
<given-names>Isabelle</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Physiology and Biophysics,</aff>
<aff id="A2"><label>2</label>Heart and Vascular Research Center, Department of Medicine, and</aff>
<aff id="A3"><label>3</label>Department of Genetics, Case Western Reserve University, Cleveland, Ohio, USA.</aff>
<aff id="A4"><label>4</label>Department of Pharmacology, Northwestern University, Chicago, Illinois, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Alfred L. George Jr., Department of Pharmacology, Northwestern University Feinberg School of Medicine, Searle 8-510, 320 East Superior Street, Chicago, Illinois 60611, USA. Phone: 312.503.4893; Email: <email>al.george@northwestern.edu</email>. Or to: Isabelle Deschênes, Heart and Vascular Research Center, 2500 Metrohealth Drive, Rammelkamp 614, Cleveland, Ohio 44109, USA. Phone: 216.778.5166; Email: <email>isabelle.deschenes@case.edu</email>.</corresp>
<fn>
<p><bold>Authorship note:</bold> E. Ficker is deceased.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-02-12T16:00:00-0500" publication-format="electronic">
<day>12</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2018-03-01T16:00:00-0500" publication-format="print">
<day>1</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>6</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>128</volume>
<issue>3</issue>
<fpage>1043</fpage>
<lpage>1056</lpage>
<history>
<date date-type="received">
<day>5</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/94996">This article is available online at https://www.jci.org/articles/view/94996</self-uri>
<abstract>
<p>Congenital long QT syndrome (LQTS) is an inherited channelopathy associated with life-threatening arrhythmias. LQTS type 2 (LQT2) is caused by mutations in <italic>KCNH2</italic>, which encodes the potassium channel hERG. We hypothesized that modifier genes are partly responsible for the variable phenotype severity observed in some LQT2 families. Here, we identified contributors to variable expressivity in an LQT2 family by using induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) and whole exome sequencing in a synergistic manner. We found that iPSC-CMs recapitulated the clinical genotype-phenotype discordance in vitro. Importantly, iPSC-CMs derived from the severely affected LQT2 patients displayed prolonged action potentials compared with cells from mildly affected first-degree relatives. The iPSC-CMs derived from all patients with hERG R752W mutation displayed lower <italic>I</italic><sub>Kr</sub> amplitude. Interestingly, iPSC-CMs from severely affected mutation-positive individuals exhibited greater L-type Ca<sup>2+</sup> current. Whole exome sequencing identified variants of <italic>KCNK17</italic> and the GTP-binding protein <italic>REM2</italic>, providing biologically plausible explanations for this variable expressivity. Genome editing to correct a <italic>REM2</italic> variant reversed the enhanced L-type Ca<sup>2+</sup> current and prolonged action potential observed in iPSC-CMs from severely affected individuals. Thus, our findings showcase the power of combining complementary physiological and genomic analyses to identify genetic modifiers and potential therapeutic targets of a monogenic disorder. Furthermore, we propose that this strategy can be deployed to unravel myriad confounding pathologies displaying variable expressivity.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Cardiology</kwd>
<kwd>Genetics</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Arrhythmias</kwd>
<kwd>Ion channels</kwd>
<kwd>iPS cells</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>NHLBI</institution>
<institution-id>https://doi.org/10.13039/100000052</institution-id>
</institution-wrap>
</funding-source>
<award-id>HL124245</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>American Heart Association</institution>
<institution-id>https://doi.org/10.13039/100000968</institution-id>
</institution-wrap>
</funding-source>
<award-id>12EIA9300060</award-id>
</award-group>
<award-group>
<funding-source>NHLBI</funding-source>
<award-id>HL105338</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>American Heart Association</institution>
<institution-id>https://doi.org/10.13039/100000968</institution-id>
</institution-wrap>
</funding-source>
<award-id>15PRE25700037</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Center for Advancing Translational Sciences</institution>
<institution-id>https://doi.org/10.13039/100006108</institution-id>
</institution-wrap>
</funding-source>
<award-id>UL1TR000439</award-id>
</award-group>
<award-group>
<funding-source>NHLBI</funding-source>
<award-id>HL105338</award-id>
</award-group>
<award-group>
<funding-source>All funding sources are listed below</funding-source>
<award-id>see below</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>